Lymphocyte transglutaminase function may be impaired in type 2 diabetes mellitus.
A method for capping of beta 2-microglobulin involving the transglutaminase inhibitor monodansylthiacadaverine was applied to lymphocytes from 17 patients with Type 2 diabetes mellitus and from a matched control group of 16 normoglycaemic healthy subjects. Monodansylthiacadaverine strongly inhibited the capping, which points to the involvement of transglutaminase in the redistribution of beta 2-microglobulin on the cell surface. The inhibition was more pronounced in lymphocytes from diabetic patients, indicating impaired transglutaminase function in Type 2 diabetes mellitus.
D002103:Cadaverine / Q000031:analogs & derivatives / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology*; D005913:Glipizide / Q000494:pharmacology; D006801:Humans; D008214:Lymphocytes / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D011940:Receptor Aggregation / Q000187:drug effects*; D011503:Transglutaminases / Q000037:antagonists & inhibitors / Q000097:blood*; D001613:beta 2-Microglobulin / Q000378:metabolism
D001613:beta 2-Microglobulin; C053510:monodansylthiacadaverine; D011503:Transglutaminases; D002103:Cadaverine; D005913:Glipizide